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As I reflect on 30 years of managing patients with pancreatic
adenocarcinoma, I wonder what I can feel good about. My
generation, including those recently retired, have certainly
brought pancreatic resection from a high risk, high mortality
procedure to a low risk, low mortality technical exercise, while
morbidity remains high. Progress in selection and in diagnosis
has allowed many patients with histopathologies other than
adenocarcinoma of the pancreas to benefit from the improve-
ments in technical skill learned by many as they confront this
lethal disease.
When one looks at survival outside of operative mortality for
resected pancreatic adenocarcinoma, few can be encouraged.
Actual disease specific survival at five years is approximately 10%
and half of those patients will go on to die of recurrent pancreatic
adenocarcinoma in the subsequent five years.1 We have made
progress in defining statistically significant factors such as nodal
positivity and margin status but that is of little help when all it
does is add or detract a percentage point or two from 10%.
Attempts at more extensive resection intended to improve local
margin and gather more lymph nodes have had at best “marginal
success.”2
In the present issue of the journal, Dr. Menon and his
colleagues provide a paper that addresses the issue of soft
tissue margin following pancreaticoduodenectomy.3 We would
all envy the surgeons at Leeds who are fortunate to have such
dedicated pathologists. They have previously demonstrated
an R1 resection rate of 85% when resected specimens are sub-
jected to a standardized and extensive pathological staging
system (the LEEP protocol). The LEEP protocol involves exten-
sive multicolor inking of the specimen with serial slices in an
axial plane. An R1 resection was then defined as tumor within 1
mm of a resected margin. The present manuscript examines 83
consecutive patients with adenocarcinoma of the pancreatic
head region. As the margin in pancreatic carcinoma is usually
limited by the surrounding vascular structures, particularly the
vena cava, the aorta and the left renal vein, have the authors
improved negative margin rate by dissection in that plane?
Without the information as to the extent of the operation then
it is hard to comment on the significance of this carefully exam-
ined margin status.
Of the 81 adenocarcinomas, 27 were primary pancreatic, 24
were ampullary and 32 of distal bile duct origin, an unusual pre-
dominance of distal bile duct cancers. The key issue of the
present manuscript addresses the high rate of margin involve-
ment, 82% in pancreatic and 72% in distal bile duct cancer. Not
surprisingly, this is far greater than what is seen in ampullary
carcinoma, 25%. Again, not surprisingly, margin positivity was
greater in more advanced T stage in all tumors. The manuscript
emphasizes that in advanced cancers, T3 or N1, a high propor-
tion will have positive margins if searched for diligently. The
study is further confabulated by the fact that the pancreatic and
distal bile duct cancers were T3 while a significant number of the
ampullary cancers were T1 or T2. The ampullary cancers were
smaller and 23 of 27 were node positive. In the pancreatic
cancers, 16 of 24 were node positive and 24 of 32 were node
positive for the distal bile duct cancers. The authors show
that the number of positive nodes was not correlated with
margin status. Only when they apply a ‘positive lymph node
rate,’ which varies between histologies, do these numbers
become significant.
Figure 2 leaps from the manuscript where patients with
pancreatic adenocarcinoma and negative margin status are sug-
gested to have an 80% 50 months actuarial survival. This con-
trasts five R0 patients with 22 R1 patients and gains statistical
significance at 0.046; surely, an example of torturing the data
until it confesses!
As three different histopathologies and all stages are included,
it is not surprising that R0 and R1 resections vary in outcome,
particularly given the association with more advanced T and N
stage. Only resection margin status in pancreatic adenocarci-
noma was significant in a univariate analysis. The table should
be read by all young faculty. We have three different pathologies,
eight different variables providing 24 comparisons, so we would
expect one of 24 to be significant by random chance. This they
have shown!
The authors’ focus on margin can therefore be misleading. It is
no surprise that margin is defined by the extent of the procedure
(and that information is not available) and the diligence of the
pathologist, for which they have admirable expertise. That
patients with small tumors who are more likely to have negative
margins do better, is not a new concept! Our surgical heritage is
replete with unproven claims that larger and more morbid pro-
cedures to gain negative margins translates into improved survival
for diseases that kill by systemic disease.
What do we take of this observation? It is clear that diligence
and pathological examination can increase the positive margin
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rate in pancreatic adenocarcinoma, but unless this can be
improved by more extended operation, it has little meaning. It is
correct that margin status is reflected in outcome as it is in so
many other diseases, but margin status alone is unlikely to influ-
ence the outcome in pancreatic adenocarcinoma, which is so poor
regardless of the underlying pathological variables.
So, what have I learned? Twenty-five years of examining
the deck chairs on the Titanic and regardless of how I rearrange
them, paint them, reappoint them or even sit in them, the
outcome remains the same.
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